Optimized Cord Blood Transplant for Adults Aged 21 to 65 With High-Risk Blood Cancers

What this Trial Is About

Researchers are studying adults with high-risk blood cancers who undergo cord blood transplants CBT using an optimized practice developed by Memorial Sloan Kettering Cancer Center. This approach standardizes patient evaluation, conditioning treatment, stem cell amounts, and follow-up care. The study aims to collect information on outcomes such as side effects, disease relapse, graft-versus-host disease GVHD, and immune system recovery after CBT. Participants receive conditioning chemotherapy including cyclophosphamide, fludarabine, thiotepa, and total body irradiation before receiving a double-unit cord blood graft infusion on day 0. GVHD prevention involves cyclosporine and mycophenolate mofetil starting three days before transplant. Patients are selected based on established guidelines for graft matching and cell doses. Optimized transplant practices are followed throughout the treatment. During the study, participants will be monitored for overall survival one year after transplant and for neutrophil engraftment up to 45 days post-transplant. Researchers will assess side effects, disease relapse, GVHD, and immune recovery through regular evaluations. The total participation duration includes pre-transplant work-up, transplant, and post-transplant follow-up extending at least one year to measure outcomes.

Cord Blood Transplant in Adults With Blood Cancers